RNS & Investor News

Half Yearly Report

30 August 2018

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces its results for the six months ended 31 May 2018.

The Company has had a strong period of growth over the last six months, announcing multiple agreements as they continue their transition from a development company into a commercial business.


To view a full version of the results in
PDF format click here


  • A US manufacturing, supply and profit sharing agreement with Cereal Ingredients, Inc for SlimBiome®
  • Completion of five successful human taste studies on SweetBiotix® demonstrating high sweetness and low off flavours
  • An exclusive royalty bearing agreement with Fine Foods and Pharmaceuticals for the production and supply of five formulations containing OptiBiotix's LPLDL® strain in Europe
  • A five year distribution agreement with Trigen Pharma International to exclusively distribute and commercialise OptiBiotix's own label CholBiome® products in Pakistan
  • A non-exclusive distribution agreement with Cambridge Commodities Ltd to distribute SlimBiome® weight management technology in the United Kingdom
  • A five year agreement with Akums Drugs and Pharmaceuticals Ltd to exclusively manufacture and supply supplements and biotherapeutic drug products containing LP-LDL® in India
  • A non-exclusive agreement with Seed Health to produce, promote, market, and commercialise products containing LP-LDL® in the USA
  • A non-exclusive license with one of the world's largest providers of dairy products to explore the potential for using OptiBiotix's SweetBiotix® technology to reduce the sugar content in a range of its dairy food products
  • The appointment of Neil Davidson as Non-executive Chairman bringing sector expertise, a network of industry contacts, and over 30 years of operational and Board experience as Chairman and Chief Executive of FTSE 100, AIM and private companies
  • Award for SlimBiome® for Weight Management Ingredient of the Year at Vitafoods 2018 and ‘Best Functional Ingredient for Health and Wellbeing' at Food Matters
  • The US launch of SlimBiome® in Cereal Ingredients Nutri-Bites® product range in March 2018
  • Independent human studies by Oxford Brookes University have demonstrated that volunteers who took SlimBiome® compared to a placebo feel fuller and are less hungry, have less food cravings, and eat less sweet and fatty foods

Post-period end highlights

  • Evaluation agreement with global dairy company for SweetBiotix®
  • US launch of LPLDL® with Seed Health
  • Manufacturing, supply and profit sharing agreement with Morley Foods
  • Exclusive license agreement for LPLDL® with ALFASIGMA S.p.A.

Stephen O'Hara, CEO of OptiBiotix, commented:"The last six months has been an exciting period of growth and development for us. We have seen a number of Board changes which reflect the continuing transition of the Company into a commercial business and have signed seven new agreements covering the USA, Asia, and Europe.As these and the total of nineteen deals we have signed since March 2017 translate into an increasing range of products and territories across the world there is an opportunity to deliver significant revenue growth. We have been particularly pleased with the increased interest from pharmaceutical companies in developing LPLDL® as a drug product called a biotherapeutic, which creates the possibility of high, value deals in a number of territories in the future.Our online store is now ready for launch and we plan to go live with it in September 2018. This will create another channel to market our products, with the potential to become a division in its own right. On behalf of the Board I would like to thank our shareholders for their continued support and we look forward to an exciting future commercialising our technology in a market forecast to become one of the world's fastest growth areas."

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).


For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Jo Turner
Tel: 020 7213 0880
finnCap (Broker)
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Tel: 020 7220 0500
Walbrook PR Ltd
Anna Dunphy
Lianne Cawthorne
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07584 391 303